Pay in 4 interest-free payments of $7.09 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
About the author Caroline Catherman Caroline Catherman is a reporter at Healthcare Brew, where she focuses on major payers, health insurance developments, Medicare and Medicaid, policy, and health tech.
New Delhi, February 26, 2025 Eli Lilly and Company today announced detailed results from ACHIEVE-3, the first head-to-head Phase 3 trial evaluating the safety and efficacy of orforglipron, a small molecule oral GLP-1 without food or water restrictions, compared with oral semaglutide in adults with type 2 diabetes inadequately controlled with metformin
Mild cognitive impairment as a risk factor for Parkinsons disease dementia
Move beyond compliance
It is administered by a licensed practitioner via the intramuscular (I.M.) or intravenous (I.V.) route, following the package insert
Ongoing Support Youll receive nutrition counseling, exercise guidance and body-composition tracking to promote fat loss while preserving muscle strength
